Dickerson LD, Gittens J, Brunning C, Jackson R, Schmid MC, Mielgo A et al.
BJS Open 2025; 9: zrae172.
The analysis included four trials with 1195 patients. Overall, neoadjuvant chemotherapy improved survival (hazard ratio 0.73, 95 per cent confidence interval 0.55 to 0.98, P=0.001), but the benefit was confined to patients with borderline resectable cancers.
Comment: Important work, with more questions than answers, among which, what is the best method for borderline cancers, and is it worthwhile at all for resectable cancers.
.png)
.jpg){kind=logo}
